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Background: The kynurenine (KYN) pathway (KP) of the tryptophan (TRP) metabolism seems to play a role in the
pathomechanism of multiple sclerosis (MS). Cuprizone (CPZ) treated animals develop both demyelination (DEM)
and remyelination (REM) in lack of peripheral immune response, such as the lesion pattern type III and IV in MS,
representing primary oligodendrogliopathy.
Objective: To measure the metabolites of the KP in the CPZ treated animals, including TRP, KYN and kynurenic
acid (KYNA). We proposed that KYNA levels might be decreased in the CPZ-induced demyelinating phase of the
animal model of MS, which model represents the progressive phase of the disease.
Methods: A total of 64 C57Bl/6J animals were used for the study. Immunohistochemical (IHC) measurements were
performed to prove the effect of CPZ, whereas high-performance liquid chromatography (HPLC) was used to
quantify the metabolites of the KP (n ¼ 10/4 groups; DEM, CO1, REM, CO2).
Results: IHC measurements proved the detrimental effects of CPZ. HPLC measurements demonstrated a decrease of
KYNA in the hippocampus (p < 0.05), somatosensory cortex (p < 0.01) and in plasma (p < 0.001).
Conclusion: This is the first evidence of marked reduction in KYNA levels in a non-immune mediated model of MS.
Our results suggest an involvement of the KP in the pathomechanism of MS, which needs to be further elucidated.1. Introduction
Multiple sclerosis (MS) is an immunemediated, chronic inflammatory
and demyelinating disease of the central nervous system (CNS). Ac-
cording to a recent study (Browne et al., 2014), roughly 2.3 million
people world-wide are affected by this disorder. It starts in young
adulthood and it has a great impact on the quality of life. The onset is
characterized by demyelination (DEM), lesions with loss of axons and
degeneration of neurons (Lassmann and Bradl, 2017). Although the
precise pathophysiology still remains to be clarified, oxidative stress is
known to play a major role in the development of the disease (Rajda
et al., 2017). Beside this, blood brain barrier (BBB) disruption and im-
mune system dysregulation (Høglund and Maghazachi, 2014), pro- and
anti-inflammatory cytokine disequilibrium (Trenova and Slavov, 2015)
and activation of glial cells (Ponath et al., 2018) were described to be
important too. As in the animal models of MS, in the human disease,
mature oligodendrocytes (OLGs) are already affected at the onset of theL. Vecsei).
m 13 November 2020; Accepted
evier Ltd. This is an open accessdisease. Microglia and macrophage activation occur to purify myelin
debris, thereby retain the myelin sheath via remyelination. Over time,
the remyelination efficiency is impaired due to the overloading of the
pathophysiological processes of demyelination. The infiltration of CNS
by peripheral immune cells (T and/or B cells) and macrophages, as well
as the activation of microglia and astrocytes within the CNS, result in the
exaggerated production of reactive oxygen species (ROS) and proin-
flammatory cytokines (Ortiz et al., 2016). Excessive ROS production and
reduced antioxidant activity leads to oxidative stress (Adamczyk and
Adamczyk-Sowa, 2016).
For the investigation and a better understanding of this disease,
several animal models are used, and one of them is the bis(cyclohex-
anone)oxaldihydrazone (Cuprizone, CPZ)-induced demyelination model
of MS (for review, see (Sen et al., 2019)).
The CPZ model aims to investigate the mechanisms of demyelination
and remyelination in lack of peripheral immune response (Sen et al.,
2019). CPZ influences the function of the mitochondrial respiratory25 January 2021
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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I-III and complex II-III (for review, see (Praet et al., 2014)). The major
histological appearance of CPZ-induced lesions is largely comparable to
the type III and IV lesion pattern in MS, which are characterized by
demyelination, oligodendroglial cell death and microglia/macrophage
activation (Sen et al., 2019). They are associated with increased levels of
ROS and reactive nitrogen species (Wakabayashi, 2002), while the BBB
remains intact (Sen et al., 2019). CPZ intoxication-induced mitochon-
drial dysfunction contributes to the loss of OLGs and axons (Kalman et al.,
2007). In early stages of the CPZ treatment the selective apoptotic death
of mature OLGs was described (Mason et al., 2001). This feature was
accompanied by oligodendroglial cell death not equally distributed in the
CNS, extended demyelination and oligodendroglial cell death occurring
in the cerebellum and the different cerebrum areas, such as corpus cal-
losum, cerebral cortex, hippocampus or striatum, but the brainstem and
spinal cord are also affected to a limited extent (Sen et al., 2019).
Remyelination starts with the accumulation of oligodendrocyte progen-
itor cells (OPC) following 3 weeks of CPZ intoxication with astrocyte and
microglia activation and it becomes evident by week 6 of CPZ treatment,
when OPCs become mature, myelinating OLGs (Praet et al., 2014).
Kynurenic acid (KYNA) is an endogenous N-methyl-D-aspartate
(NMDA) receptor antagonist, which is produced by the kynurenine
(KYN) pathway (KP) (Figure 1), whereas KYN is an intermediate
metabolite of the KP, which can be metabolized via three different
pathways to form KYNA, xanthurenic acid or nicotinamide adenine
dinucleotide (NADþ) (Vecsei et al., 2013). KYNA is produced by KYN
aminotransferases (KATs) and it can influence the glutamatergic trans-
mission in different ways (Zadori et al., 2011), i.e., it behaves as aFigure 1. The kynurenine metabolite pathway. 3-HAO 3-hydroxyanthranilate oxid
kynurenine aminotransferase, KMO kynurenine 3-monooxygenase, NADþ nicotineam
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competitive antagonist on the NMDA receptor (Kessler et al., 1989) and
has weak antagonistic effects on the AMPA- and kainate receptors (Birch
et al., 1988). Furthermore, KYNA is a potent endogenous aryl
hydrocarbon-receptor ligand, suggesting a significant immunomodula-
tory role too (Bohar et al., 2015). The KP shows alterations in different
neurological disorders, including MS (for review, see (Vecsei et al., 2013;
Zadori et al., 2011, 2009). While in relapsing MS the KP is shifted to-
wards the neurotoxic metabolite quinolinic acid (QUIN), the progressing
form is characterized by decreased KYNA levels (Lim et al., 2017;
Lovelace et al., 2016).
Based on the above mentioned data, the aim of the current study was
to measure the metabolites of the KP in CPZ treated animals, including
TRP, KYN and KYNA. We proposed that KYNA levels might be decreased
in the CPZ-induced demyelinating phase of the animal model of MS, as
this the best model, which represents the progressive phase of the disease.
2. Materials and methods
2.1. Animal experiments and sample collection
Eight weeks old (20–25 g) male C57Bl/6J mice were used (n ¼ 64).
The animals were bred and maintained under standard laboratory con-
ditions with 12 h–12 h light/dark cycle at 24 1 C and 45–55% relative
humidity in the Animal House of the Department of Neurology, Uni-
versity of Szeged. The studies were in accordance with the Ethical Codex
of Animal Experiments and were approved by the Committee of the
Animal Research of University of Szeged (I-74-49/2017) and were
authorized by the National Food Chain Safety Office with a permissionase, IDO/TDO indoleamine 2,3-dioxygenase/tryptophan 2,3-dioxygenase, KAT
ide adenine dinucleotide.
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Animals in Research of the International Association for the Study of Pain
and the directive of the European Parliament (2010/63/EU). The animals
were housed in groups of 4–5 in polycarbonate cages (530 cm3 floor
space). Prior to the experiment, the animals were habituated to grounded
standard rodent chow, and they were measured every other day.
DEM was induced by feeding mice a diet containing 0.2% CPZ (bis-
cyclohexanone–oxaldihydrazone; Sigma-Aldrich, n ¼ 36) mixed into a
grounded standard rodent chow for 5 weeks. Age matched animals were
used as controls (n¼ 28), which also had free access to grounded standard
rodent chow and water. At the end of the five-week treatment period, in
both cuprizone (CPZ) treated (n ¼ 36) and control (CO) group (n ¼ 28)
half of the animals (CPZ DEM: n ¼ 18, CO n ¼ 14) were randomly chosen
and sacrificed, as detailed below. At the end of 5-weeks of treatment, after
perfusion, the cuprizone diet was excluded and from the 6th week on-
wards, the surviving animals participated in the remyelination (REM)
phase for 4 weeks. At the end of the last week, the remaining animals were
sacrificed (CPZ REM: n ¼ 18, CO n ¼ 14) as detailed below. Behavioral
tests were performed during both the DEM and REM phases of the
experiment (Figure 2). During the experiment, two animals died: one died
in cage at the beginning of the remyelination phase in the CPZ treated
group, presumably due to the change of the hierarchy between males,
whereas the second one from the CO group died at the end of the
remyelination phase, during anesthesia, right before perfusion.
The mice were anesthetized with intraperitoneal 4% chloral hydrate
(10 ml/kg body weight). For the histological and immunohistochemical
(IHC) studies mice (CPZ: n ¼ 16, CO: n ¼ 8) were perfused transcardially
with artificial cerebrospinal fluid followed by 4% paraformaldehyde in
0.1 M phosphate buffer. Brain samples were dissected and postfixed in
the same fixative overnight at 4 C. Brains were embedded in paraffin,
coronally sectioned in 8 μm thickness obtained from different regions
(0.14, 0.22, 1.06, and 1.94 mm) according to the mouse brain atlas
of Paxinos and Franklin (2001) and placed on gelatin-coated slides (Acs
et al., 2009). For bioanalytical measurements, the animals (CPZ: n ¼ 20,
CO: n ¼ 20) were anesthetized and perfused as described above. Blood
samples were taken from the left heart ventricle into Eppendorf tubes
containing disodium ethylenediaminetetraacetate dihydrate and the
plasma was separated by centrifugation (3500 rpm for 10 min at 4 C).
The brains were dissected into five different brain regions, including the
cerebellum, brainstem, striatum, somatosensory cortex and hippocam-
pus. All samples were removed on ice and stored at -80 C until further
use. The treated and recovered mice were marked as groups DEM and
REM, respectively, whereas age matched animals as controls became the
CO1- and CO2 group.2.2. Luxol Fast Blue (LFB) staining and myelin status analysis
Myelin damage was evaluated with Luxol Fast Blue-Cresyl-Violet
(LFB/CV) staining. The brain slides were deparaffinized, rehydrated3
with 95% alcohol and incubated in a 0.01% LFB solution overnight at 60
C, after that the sections were differentiated in 0.05% lithium carbonate
solution and counterstained with CV.2.3. Immunohistochemical and intensity measurement analysis
For IHC analysis gelatin-coated slides were deparaffinized, rehy-
drated and heat-unmasked in 10 mM citrate buffer. Sections were
blocked with 0.3% hydrogen peroxide in phosphate-buffered saline
(PBS) solution and incubated with the primary antibody diluted in a
solution containing 0.1 M PBS and 10% normal goat or horse serum
overnight. Anti-glial fibrillary acidic protein (GFAP, 1:500, rabbit IgG,
Dako, Agilent) for astrocyte visualization and anti-myelin basic protein
(MBP, 1:500, mouse IgG, Abcam) to detect myelin were applied.
Adequate biotinylated secondary antibody was used and the ABC Kit
(Vectastain Kit, Vector Laboratories) and 3,30-diaminobenzidine (DAB)
reaction was used for visualization. For measurements an AxioImager M2
microscope, equipped with an AxioCam MRc was used. Rev 3 camera
(Carl Zeiss Microscopy) and AxioVision 4.8 software (Carl Zeiss Micro-
scopy, Germany) program were applied. Quantification of astrogliosis
was achieved by manual cell counting of the GFAP-immunopositive cells
in the corpus callosum (CC). Intensity measurement was used to deter-
mine myelin content with MBP and LFB staining.2.4. High-performance liquid chromatography (HPLC) measurement
Chromatographic separation was carried out with a validated
method, as described before (Cseh et al., 2019). Briefly, on the day of
measurement, plasma and brain samples were deproteinized by precip-
itation as described before (Cseh et al., 2019). The mobile phase, in each
case was a 200 mM zinc acetate solution, at final pH of 6.2 for plasma,
and 5.8 for brain tissue samples, with a final concentration of 5 % of
acetonitrile. Regarding the LOD values, in brain samples it was 0.259
nmol/g ww for KYN and 1.82 for KYNA, whereas in plasma samples it
was 1.33 nM for KYNA.2.5. Behavioral investigation
During the open field test, each animal (n¼ 18/group) in CPZ treated
and CO groups was placed in the center of an open-field box measuring
48 * 48 * 40 cm for 15 min tracking periods (analyzed in three 5 min
periods). The movement patterns of the animals were tracked and
recorded with the Conducta 1.0 system (Experimetria Ltd.). The pa-
rameters recorded were the ambulation distance, the time spent in
immobility and the total time spent with consecutive rearing (Veres et al.,
2015). Open field measurements were carried out in the third, fourth and
fifth week of CPZ treatment and in the third and fourth week of the
remyelination phase, once a week on the same day, in the morning.Figure 2. Timeline of the experimental
procedure applied in this study. CPZ cupri-
zone; CO control; IHC immunohistochemical
studies; HPLC High-performance liquid
chromatography; ¥One animal died in cage at
the beginning of the remyelination phase in
the CPZ treated group and at the end of the
remyelination phase, an animal also died in
the CO group before perfusion. n represents
the number of animals used in one group.
*Sample collection was randomly selected in
the CPZ treated- and the CO group.
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function. The animals in the CPZ and CO groups (n ¼ 18 animals/group)
were trained on the rotarod for a 3-session period for 5 min on 2
consecutive days prior to the first test day. On the first and second days of
the training sessions, a constant speed of 5 and 10 rpm respectively, was
used. The test was performed on the third, fourth and fifth week of CPZ
treatment and on the third and fourth week of the remyelination phase,
once a week on the same day following the training sessions. The per-
formance of each mouse was measured three times with resting periods
of 30 min between consecutive tracking sessions. The latencies to fall
values were recorded with the TSE Rotarod Advanced system. In the test
phase, rodents were placed on a rotating rod, with a constantly increasing
speed from 5 to 40 rpm during the 300 min test period. On the day before
the respective test day, a 3 session retraining at 10 rpm for 5 min with 30
min resting periods was carried out to enable the animals to recall the
rotarod experience (Veres et al., 2015).2.6. Statistical analysis
For the quantitative analysis of GFAP-immunopositive cells and the
analysis of intensity measurement of LFB and MBP statistical differences
were determined by one-way analysis of variance (ANOVA) followed by
the Sidak or Tamhane's T2 post hoc test depending on variances of data,
with p< 0.05 taken as statistically significant. For statistical comparison of
the bodyweight andbehavioralmeasurements,weused two-way repeated-
measuresANOVA.Pairwise comparisons of groupmeanswerebasedon the
estimated marginal means with Sidak or Tamhane's T2 post hoc test with
adjustment for multiple comparisons. Group values are reported as means
 SEM, analyses were performed in SPSS Statistics software (version 20.0
for Windows, SPSS Inc). Regarding the HPLC measurements, if the distri-
bution (Shapiro–Wilk test) was proven to be Gaussian and the variances
were equal (Levene test) ANOVAwas appliedwith TukeyHSDpost hoc test
for pairwise comparison, otherwise Kruskal-Wallis, with theWilcoxon post
hoc test was used. Data were plotted as median (1st‒3rd quartile).
3. Results
3.1. Body weight
On the third day of CPZ treatment, there was already a significant
difference in the body weight of the CPZ group compared to the CO groupFigure 3. Changes in body weight of the animals during observation. CO controls, de
dots within two periods (demyelination- and remyelination phase) indicated with b
4
(Figure 3). This difference remained until the beginning of the REM
phase. However, this difference disappeared during the REM phase and
the body weight of the two groups returned to the same range by the end
of the experiment.
3.2. Determination of CPZ damage after DEM and REM phase
Five weeks of CPZ feeding (acute DEM phase) resulted in an extensive
and significant demyelination in the CC, as shown by LFB/CV (Figure 4)
and MBP staining (Figure 5, Figure 7). This myelin damage was
ameliorated at week four after REM. Immunostaining with GFAP cells
(Figure 6) within the CC showed an extensive astrogliosis in the CPZ
treated groups (DEM and REM) compared to the CO group (Figure 7).
3.3. Behavioral tests
There were no significant differences between the CPZ- and CO
groups during the DEM- or REM phase in any of the measured parameters
in either the open field test (Figure 8), or in the rotarod test (Figure 9).
3.4. HPLC measurement of tryptophan metabolites from brain and plasma
samples
The mentioned five brain regions, i.e., cerebellum, brainstem, stria-
tum, somatosensory cortex and hippocampus were analyzed during the
bioanalytical measurements. All measured concentrations are presented
in Table 1 including the ones from plasma samples. The boxplots repre-
sent only the significant changes observed after the sample measure-
ments, namely the significant decrease of KYNA in the hippocampus
(Figure 10A), cortex (Figure 10B) and plasma (Figure 10C). As the data
distribution was not normal (p > 0.05), data were presented as mean (1st
and 3rd quartile range). The other three metabolites (TRP, KYN and se-
rotonin (5-HT)) did not change significantly in the assessed brain regions.
4. Discussion
In the present study, we investigated tryptophan and the metabolites
of the KP in the CPZ-induced demyelination model. In this animal model
of progressive form of MS, the demyelination occurs in the absence of
inflammation, which in turn gives an opportunity to study neurode-
generative processes. Our findings show that CPZ intoxication caused anpicted with blue dots; CPZ cuprizone treated animals are highlighted with orange
lack arrows. *p < 0.05 vs. CO, ***p < 0.001 vs. CO.
Figure 4. LFB staining in the corpus callosum of the CO- (A), DEM- (B) and REM (C) group. The CPZ-treated group (B) showed a reduced myelin content compared to
the CO group (A), which increased during the remyelination phase (C). Scale bar: 200 μm. CO control group, CPZ cuprizone treated group, DEM demyelination phase
in the treated group, LFB Luxol Fast Blue, REM remyelination phase in the treated group.
Figure 5. Myelin content determination of the corpus callosum with MBP staining in the CO (A), DEM (B) and REM (C) group, where the CPZ demyelination group (B)
showed less myelin content, which increased in the remyelination phase (C). Scale bar: 200 μm. CO control group, CPZ cuprizone treated group, DEM demyelination
phase of the treated group, MBP myelin basic protein, REM remyelination phase of the treated group.
Figure 6. GFAP immunostaining in the corpus callosum of the CO- (A), DEM- (B) and REM (C) group. In the CO group (A) only a few astrocytes were present in the
CC. During CPZ treatment an extensive astrogliosis was observed in the CPZ group (B), which persisted during remyelination phase (C). Scale bar: 200 μm. CO control
group, CPZ cuprizone, DEM demyelination group, GFAP glial fibrillary acidic protein, REM remyelination group.
Figure 7. Effect of CPZ administration on myelination of the CC in the CO-, DEM- and REM group. LFB/CV (A) and MBP (B) staining for myelin content determination
by intensity measurement. Immunohistochemical staining for GFAP (C) in the CC. Quantification of astrogliosis was done by manual cell counting. Our results show
that the CPZ treatment caused a significant decrease in myelin content and an extensive astrogliosis in the CPZ group compared to the CO group. CC corpus callosum,
CO control group, DEM demyelination group, GFAP glial fibrillary acidic protein, LFB Luxol Fast Blue, MBP myelin basic protein, REM remyelination group, *p < 0.05
vs. CO, **p < 0.01 vs. CO, ¥p < 0.05 vs. REM, ***p < 0.001 vs. CO, ###p < 0.001 vs. CO.
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gliosis at the onset of acute demyelination, thereby reproducing the
results previously described in the literature (Praet et al., 2014; Sen
et al., 2019) and proving the CPZ model works properly in our case too.5
Behavioral tests did not show significant differences between experi-
mental groups. These results are also in line with prior data, regarding
both rotarod performance, and open field test. However, results on
behavioral effects of CPZ are rather controversial (for a detailed review,
Figure 8. Open field test results. Data are presented as the total ambulation distance in the CO-, DEM- and REM groups. CO control group, CPZ cuprizone treated
group, DEM demyelination phase in the treated group, REM remyelination phase in the treated group, n ¼ 18/group.
Figure 9. Rotarod investigation results. Data are presented as the total time spent on the rod in the CO-, DEM- and REM groups. CO control group, CPZ cuprizone
treated group, DEM demyelination phase of the treated group, REM remyelination phase of the treated group, n ¼ 18/group.
H. Polyak et al. Heliyon 7 (2021) e06124see (Sen et al., 2019)). In our study, CC was used for IHC measurements,
a choice based on other IHC data from literature, item due to the small
area of this structure and its unreliable preparation, while for bio-
analytical measurements, we selected the brain regions most affected by
demyelination and oligodendroglial cell death in the CPZ model (Praet
et al., 2014; Sen et al., 2019), but we wanted to expand this spectrum, so
we decided to quantify from the remaining brain regions too.
During the examination of the KP metabolites, a significantly
decreased KYNA concentration was observed in the CPZ treated DEM
group compared to the CO group in the acute demyelination phase, in the
cortex and the hippocampus, which difference disappeared during the6
REM phase, with no significant differences between the samples of the
REM group compared to the CO samples. The same pattern was observed
in the plasma samples. TRP showed no significant differences in either
CNS or blood samples, similarly to the results of Goldberg and his co-
workers (Goldberg et al., 2013) in liver function test with no difference in
plasma TRP levels between CPZ treated- and control groups. Further-
more, no significant difference was found in KYN and 5-HT levels be-
tween the groups during the experiment. This suggests that CPZ may
influence KYNA levels directly.
The presumed direct effect of CPZ may derive from the inhibition of
KYNA synthesis. Four isoforms of KAT are responsible for the formation
Table 1. Concentration levels of tryptophan, kynurenine, kynurenic acid and serotonin.
CO1 (n ¼ 10) DEM (n ¼ 10) CO2 (n ¼ 9y) REM (n ¼ 10)
Hippocampus
TRP (nmol/g ww) 14.7 (13.9–19.9) 17.3 (15.6–18.3) 16.21 (13.1–16.9) 15.8 (14.8–18.1)
KYN (nmol/g ww) <LOD <LOD <LOD <LOD
KYNA (pmol/g ww) 15.5 (4.75–27.1) <LOD* (<LOD ‒3.52) 5.61 (1.94–17.4) 4.61 (3.06–11.8)
5-HT (pmol/g ww) 3777 (3415–3978) 3813 (3538–3996) 4096 (3720–4119) 3824 (3607–4095)
Somatosensory Cortex
TRP (nmol/g ww) 18.1 (16.4–22.2) 18.9 (17.9–20.6) 28.9 (25.2–30.6) 14.2 (4.25–20.2)
KYN (nmol/g ww) <LOD <LOD <LOD <LOD
KYNA (pmol/g ww) 10.7 (6.20–12.1) <LOD**,#,¥ 11.9 (<LOD ‒15.6) 14.2 (4.25–20.2)
5-HT (pmol/g ww) 3916 (3477–4364) 4064 (3597–4317) 3322 (3208–3777) 3442 (2640–3969)
Striatum
TRP (nmol/g ww) 20.6 (18.0–23.6) 18.7 (16.9–20.2) 17.1 (16.2–18.8) 17.1 (14.8–19.2)
KYN (nmol/g ww) <LOD <LOD <LOD <LOD
KYNA (pmol/g ww) 10.7 (7.19–22.1) <LOD (<LOD‒3.66) 3.82 (<LOD‒10.0) 10.5 (6.42–20.3)
5-HT (pmol/g ww) 3943 (3654–4218) 3958 (3254–4453) 3831 (3580–4476) 3765 (3663–4236)
Cerebellum
TRP (nmol/g ww) 18.0 (16.0–34.5) 19.6 (17.0–21.1) 16.9 (13.5–20.0) 18.3 (15.5–22.4)
KYN (nmol/g ww) 0.367 (<LOD‒0.439) <LOD <LOD <LOD
KYNA (pmol/g ww) 7.3 (5.25–12.0) <LOD 12.0 (3.05–17.7) 4.70 (2.25–7.89)
5-HT (pmol/g ww) 1734 (1533–2026) 1490 (1411–1962) 1477 (1066–3216) 1639 (1307–2453)
Brainstem
TRP (nmol/g ww) 14.9 (13.9–21.1) 14.5 (12.3–17.3) 12.4 (12.2–18.1) 11.1 (9.72–11.9)
KYN (nmol/g ww) <LOD <LOD <LOD <LOD
KYNA (pmol/g ww) <LOD <LOD <LOD <LOD
5-HT (pmol/g ww) 4936 (4125–5189) 4302 (4127–4822) 4365 (2312–4520) 4121 (3931–4183)
Plasma
TRP (μM) 28.7 (24.6–32.6) 38.3 (33.9–42.3) 37.9 (36.3–43.0) 31.56 (29.85–39.73)
KYN (μM) 1.37 (0.635–1.72) 1.35 (0.843–1.64) 1.08 (0.578–1.29) 1.16 (0.814–1.39)
KYNA (nM) 41.92 (32.0–58.8) <LOD***,###,¥¥¥ 42.4 (40.7–46.9) 38.8 (36.1–50.6)
5-HT serotonin, CO1 – control group belonging to the cuprizone treated group (DEM) in the demyelination phase; CO2 – control group in the remyelination phase, DEM
demyelination group, KYN kynurenine, KYNA kynurenic acid, LOD limit of detection, REM remyelination group, TRP tryptophan, ww wet weight.
*p < 0.05 vs. CO1, **p < 0.01 vs. CO1, ***p < 0.001 vs. CO1,#p < 0.05 vs. CO2,###p < 0.001 vs. CO2, ¥p < 0.05 vs. REM, ¥¥¥p < 0.001 vs. REM.
y one animal died in cage after anesthesia.
Figure 10. Significant decrease of kynurenic acid concentration in the cuprizone treated group (demyelination group). n ¼ 10/group, except DEM, where one animal
died in cage after anesthesia. CO1 – control group belonging to the cuprizone treated group (DEM) in the demyelination phase; CO2 – control group in the remyelination phase,
DEM demyelination phase of the treated group, KYNA kynurenic acid, REM remyelination phase of the treated group, wwwet weight. *p < 0.05 vs. CO1, **p < 0.01 vs.
CO1, ***p < 0.001 vs. CO1, #p < 0.05 vs. CO2, ###p < 0.001 vs. CO2, ¥p < 0.05 vs. REM, ¥¥¥p < 0.001 vs. REM.
H. Polyak et al. Heliyon 7 (2021) e06124of KYNA, with a predominant role of KAT II in mouse liver, and KAT IV in
adult mouse brain (Guidetti et al., 2007). The increased concentration of
Cu2þ inhibits the KAT enzymes, thus it may affect the concentration of
KYNA (El-Sewedy et al., 1974). Moreover, CPZ alters the Cu2þ, Mn2þ and
Zn2þ homeostasis in plasma, kidney, liver and in some brain regions
(Moldovan et al., 2015). The explanation seemed to be the decrease in
the amount of copper-dependent enzymes (Venturini, 1973) which led to
the increase of copper and which further led to the inhibition of the KAT7
enzyme, and as a consequence to the decrease of KYNA. Although it is not
thoroughly studied in the CPZ model, other models of MS have described
the expression of KAT enzymes, namely KAT I and KAT II, which were
significantly down-regulated in the CNS tissues of the severe experi-
mental autoimmune encephalomyelitis (EAE) mice, accordingly
decreased KYNA levels were observed in the tissues (Sundaram et al.,
2020). Furthermore, this was simultaneously supported by increased
kynurenine 3-monooxygenase (KMO) enzyme expression in the CNS
Figure 11. Structural formula of KYNA and laquinimod
H. Polyak et al. Heliyon 7 (2021) e06124tissues examined, that is the KYNA/QUIN ratio was significantly
decreased in the EAE mice compared to the control group (Sundaram
et al., 2020).
On the other hand, CPZ may alter the KYNA synthesis via damaging
astrocytes. During intoxication, damaged astrocytes appear, with
morphological change and become hypertrophic (Praet et al., 2014),
with an extensive astrogliosis. We can assume that this astrocyte acti-
vation also alters KYNA synthesis.
It is also possible that the KP is shifted towards neurotoxic metabolites
and this is responsible for the decrease in KYNA concentration. The CPZ
model is an rodent model of progressive form of MS to investigate the
demyelination and remyelination without immune response (Sen et al.,
2019). In our study, we found a decreased KYNA concentration in the
CPZ-treated DEM group during demyelination, however, in human MS
studies, elevated KYNA levels have been reported during active relapse
phase, and decreased during remission, as well as in progressive forms of
the disease (Lim et al., 2017; Lovelace et al., 2016; Rajda et al., 2015;
Vecsei et al., 2013). This observation raises the possibility, that the KP
has a complex role in the pathomechanism of MS, it behaves differently
in short and long term, and it responds differently in immune-mediated
and non immune-mediated conditions, as MS is an immune-mediated
disease of CNS, in which the KP, including the IDO enzyme, is greatly
affected by the immune pathways (Vecsei et al., 2013). Nevertheless, the
CPZ-induced demyelination model is a primary oligodendropathy model
(Praet et al., 2014), and although it cannot induce inflammation, it af-
fects the KP.
In the CPZ-induced model, microglia and macrophage activation
occur in the early stages of demyelination (Praet et al., 2014). Further-
more, myelin debris has a regulatory function for microglia activation,
phagocytosis and consequently the process of remyelination (Kotter
et al., 2006; Skripuletz et al., 2013). Within CPZ-induced demyelinated
lesions, both pro-, and anti-inflammatory phenotypes can be attributed to
microglia (for a detailed review, see (Praet et al., 2014). In a previous
study, macrophage/microglia cells were described as the major QUIN
expressors (Guillemin et al., 2003), suggesting that a prolonged inflam-
matory response may elicit an elevation in QUIN concentration in a
pathophysiological range (Sundaram et al., 2020). Moreover, it has been
reported, that QUIN produced by activated monocyte cells, in patho-
physiological concentration can cause neuronal and glial cell death
(Guillemin et al., 2001), and these cells are capable of inducing demye-
lination by direct association with oligodendrocytes (Yamasaki et al.,
2014).
In the light of the above provided literature information, in the CPZ-
induced demyelination model, KP may shift in a neurotoxic direction,
which may be responsible for the drastic decrease of the KYNA level.
The CPZ-induced mitochondrial dysfunction, consequent energy
deficit and increased oxidative stress may initiate a cascade, which re-
sults in demyelination and neurodegeneration (Praet et al., 2014). In this
concept, CPZ may not inhibit the synthesis, merely KYNA is consumed in8
larger quantities than it is formed, due to its ROS scavenger effect (Vecsei
et al., 2013). Because of its involvement in the above mentioned poten-
tially neurotoxic processes, KYNA is considered a neuroprotective agent
(Bohar et al., 2015). Consequently, due to the fact, that in our study the
levels of KYNA decreased both in plasma and CNS, we assume, that its
protective property is less pronounced, whereas the neurodegeneration is
way more enhanced, thus the excitotoxicity may be more significant.
In a recent study (Nedelcu et al., 2020) the well-known small mole-
cule laquinimod ‒ showing structural similarities with KYNA (Figure 11)
‒was described to be capable to ameliorate inflammatory demyelination,
metabolic OLG injury, with further anti-inflammatory effects in the CPZ
model. Furthermore, it has potential benefits in clinical cases by sup-
pressing the development of active lesions in relapsing-remitting MS
(Comi et al., 2008; Polman et al., 2005). In addition, laquinimod is able to
reduce the degree of axonal damage and demyelination, as well as in-
flammatory lesions in the EAE model of MS (Aharoni et al., 2012; Brück
et al., 2012). Moreover, laquinimod influences the glutamatergic and
GABAergic transmission in the striatum of EAE mice (Ruffini et al.,
2012). In a recent in vitro study, it was proved, that laquinimod improved
cerebral glutamatergic transmission on cerebellar slices of EAE mice
(Gentile et al., 2018). It seems, that the exogenously administered KYNA
analogue is able to reduce the degree of damage therefore it is assumed
that the KYNA is consumed during demyelination.
The limits of our study are the relatively few measured KP metabo-
lites, and the lack of cognitive function tests during behavioral
investigation.
Nevertheless, this is the first study assessing some of the TRP me-
tabolites changes in five different brain regions and plasma after CPZ
treatment, confirming decreased KYNA levels in both sides of the blood-
brain barrier during demyelination. These findings support the involve-
ment of the KP in the pathogenesis of MS. Although the above-described
theories serve as an initial hypothesis, it is clear that further studies are
needed to be conducted to determine, what is the exact mechanism of the
reduction in KYNA level during CPZ treatment and how this phenomenon
may be related to de- and remyelinating processes and the possible ef-
fects of the KP on demyelination of the CNS. Our future plan is a detailed
exploration of the KP in the CPZ intoxicated mouse model, besides on the
use of specific agonists and antagonists of the KP.
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